- TITLE: Impact of Remote Cholecystectomy on Clinical Outcomes Following Pseudomonas 1
- 2 aeruginosa Bloodstream Infection: A Retrospective Cohort Study
- 4 **AUTHORS:** Hanna K. Bertucci^{a,*}, Lyndsey R. Heise^{a,b,*}, Michael P. Angarone^a, Alan R.
- Hauser^{a,c}, Marc H. Scheetz^{a,d,e}, Kelly E. R. Bachta^{a,#} 5

AFFILIATIONS:

- 8 ^aDepartment of Medicine, Division of Infectious Diseases, Northwestern University, Feinberg
- 9 School of Medicine, Chicago, Illinois, USA
- ^bDepartment of Infectious Diseases and Travel Medicine, Springfield Clinic, Springfield, Illinois, 10
- 11 **USA**

17

20

23

3

6

- 12 ^cDepartment of Microbiology-Immunology, Northwestern University, Feinberg School of
- 13 Medicine, Chicago, Illinois, USA
- 14 ^dDepartments of Pharmacy Practice and Pharmacology, Pharmacometric Center of Excellence,
- 15 Midwestern University, Chicago College of Pharmacy, Downers Grove, Illinois, USA
- 16 ^eDepartment of Pharmacy, Northwestern Medicine, Chicago, Illinois, USA
- *Co-first authors: Hanna K. Bertucci and Lyndsey R. Heise contributed equally to this work. 18
- 19 Author order was determined after shared discussion.
- *Corresponding author: Kelly Bachta, kelly.bachta@northwestern.edu, ORCID: 0000-0001-21
- 22 8838-5117

KEYWORDS

24

25

26

27

31

32

Pseudomonas aeruginosa, cholecystectomy, antimicrobial resistance, bloodstream infection

ABBREVIATIONS

- 28 Pseudomonas aeruginosa (Pa); Pseudomonas aeruginosa bloodstream infection (PABSI);
- 29 bloodstream infection (BSI); antimicrobial resistance (AMR); multidrug-resistant (MDR),
- extensively drug-resistant (XDR); gallbladder (GB); gastrointestinal (GI)

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

ABSTRACT: Purpose: Mortality associated with Pseudomonas aeruginosa bloodstream infection (PABSI) remains high despite advances in clinical care and therapeutics. In a recent study using mice to model PABSI, the gallbladder (GB) was identified as a reservoir for bacterial expansion. Furthermore, bile exposure has been linked to increased antimicrobial resistance (AMR). Therefore, we asked whether patients with retained gallbladders might suffer from more antimicrobial resistant P. aeruginosa (Pa) infections, extended culture positivity, and worsened clinical outcomes. Methods: Retrospective cohort study of adults hospitalized over a five-year period with PABSI. PABSI cases were defined as patients with ≥ 1 positive Pa bacterial culture from the blood. Patients were categorized as either those retaining a gallbladder (no cholecystectomy) or those without (cholecystectomy). Cholecystectomy was defined as a history of cholecystectomy ≥ 1 year prior to the index episode of PABSI. Inferential statistics were used to identify associations between remote cholecystectomy and antimicrobial resistance profile, length of blood culture positivity, and in-hospital and 90-day mortality. Results: The final study population included 336 patients, 262 (78%) with retained gallbladder and 74 (22%) without. We observed no difference in 90-day or in-hospital mortality between groups. Overall, composite 90-day mortality was 30.1%. Furthermore, no robust differences were observed in the antimicrobial resistance profile of *Pa* isolates between the groups. Conclusions: In our study, neither PABSI AMR pattern nor clinical outcome was affected by remote cholecystectomy. However, we do demonstrate that mortality for patients with PABSI in the modern era remains high despite advances in anti-pseudomonal therapeutics.

INTRODUCTION

Bloodstream infections (BSIs), as defined by the ability to culture bacteria from the bloodstream of a patient with signs of systemic infection, are a growing threat to public health. It is estimated that over 575,000 cases of BSIs occur annually in North America leading to over 90,000 patient deaths per year [1]. Positive blood cultures in the context of infection have been shown to increase overall mortality risk and BSIs are a leading cause of sepsis, an often-devastating consequence of infection. Hospitalization due to BSI lasts up to 20 days longer than other admissions, leading to significant economic consequences for the patient and increased resource burden on healthcare systems [2]. In patients whose BSI progresses to clinical sepsis, the average length of hospitalization increases by 75% making sepsis the most expensive condition to treat in the hospital [3, 4]. Sepsis is often fatal and those patients who do survive are more likely to have permanent organ damage and physical and mental impairments [4]. Among all bacterial organisms that cause BSIs, Gram-negative organisms are increasing at an alarming rate.

One such organism is *Pseudomonas aeruginosa* (*Pa*). *Pa* is an opportunistic, environmental Gram-negative bacterium, that commonly causes healthcare-associated infections including BSI. *Pa* is the 4th leading cause of BSIs, comprising approximately 4-9% of all episodes [5, 6]. Compared to all other bacterial species, BSI secondary to *Pa* carries a disproportionately high risk of mortality [7, 8] with reported crude mortality rates ranging widely from 20 to 70% [7-11]. A 13-year prospective study that evaluated 2600 patients with BSI and adjusted for antimicrobial resistance (AMR) patterns and comorbidities, found that the mortality for *Pa* BSI (PABSI) was higher than that of all other bacterial pathogens including *Staphylococcus aureus* [7]. PABSI is typically acquired in situ via central venous catheters, or secondarily following dissemination from an invasive infection such as pneumonia or urinary tract infection [11, 12]. Risk factors for PABSI include prolonged hospitalization, neutropenia, liver and biliary disease, immunodeficiency, the presence of an indwelling catheter and prior

gastrointestinal (GI) colonization with *Pa* [10, 13-16]. Factors such as delayed effective antibiotic treatment, neutropenia, underlying pneumonia, and more severe disease at time of presentation have been associated with poor PABSI outcomes [9, 17]. Additionally, rising AMR rates worsen the prognosis for PABSI. Multidrug-resistance (MDR) rates for *Pa* are among the highest of all BSI-causing pathogens, occurring in more than a quarter of all isolates [5]. Given the rise in drug resistance, *Pa* is one of the top two pathogens frequently initially treated with inappropriate antibiotic therapy [18], and inadequate or delayed onset of antibiotic therapy has been shown to worsen prognosis [17, 18]. Despite the development of newer antimicrobial combinations to combat rising AMR (e.g. ceftazidime-avibactam and ceftolozane-tazobactam), limited headway has been made in reducing overall PABSI mortality likely related to an incomplete understanding of pathophysiology.

In a recent report, Bachta, et al. used a mouse infection model to better understand PABSI intra-host infection dynamics [19]. Notably, following PABSI, Pa was found to traffic to the gallbladder (GB) where the population expanded dramatically and facilitated high levels of excretion of Pa into the gastrointestinal (GI) tract. Remarkably, post infection, the gallbladder contained the highest bacterial burden of any organ. Removal of the gallbladder led to dramatic reductions in the fecal excretion of Pa, thereby suggesting that the gallbladder may be a previously underappreciated niche for Pa expansion. Pa was also shown to replicate robustly in bile *in vitro*. In human studies evaluating the causative agents of cholecystitis and cholangitis, Pa is among the top five most frequently isolated pathogens [20, 21], and its presence in the gallbladder has been associated with the development of secondary sclerosing cholangitis [22].

The gallbladder acts as an important reservoir for bile, a complex mixture of bile acids, phospholipids, cholesterol, bilirubin, inorganic salts and trace metals [23]. Bile is one of the most inherently bactericidal compounds in the human body, serving to decrease bacterial burden in the GI tract. Several studies have demonstrated that the gallbladder is an important replicative niche for certain bacterial species. It has been shown to facilitate persistent

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

colonization and enhance transmission of Salmonella typhi, Listeria monocytogenes and Campylobacter jejuni [24-27]. Gallbladder epithelial cells serve as the niche for in vivo replication of Salmonella enterica serovar Typhi [28] and L. monocytogenes replicates within the lumen of the murine gallbladder [29]. As in PABSI, mouse models of BSI demonstrated that L. monocytogenes also traffics to the liver and gallbladder and is subsequently excreted in the GI To promote survival and GI colonization, bacteria have developed tract [26, 30, 31]. mechanisms that subvert the toxic effects of bile through adaptation and tolerance [24], and many utilize bile as a signal to enhance virulence gene regulation for efficient infection [24]. L. monocytogenes expresses a bile salt hydrolase that, when deleted, decreases virulence [32]. Exposure to bile promotes germination of *Clostridioides difficile*, an important cause of infectious colitis in patients. Other mechanisms that promote bile tolerance include induction of biofilm formation and intracellular invasion of gallbladder epithelial cells, a phenomenon thought to promote chronic carriage and GI shedding of Salmonella [33]. Critically, bile exposure has been linked to promotion of increased antimicrobial resistance. There is mounting evidence in *E. coli*, Enterobacter cloacae, Klebsiella pneumoniae, Acinetobacter baumannii, and Pa that bile exposure stimulates efflux pump expression enhancing the ability of bacteria to survive in harsh environments [24, 34]. For example, bile exposure in E. coli increases expression of multidrugefflux pumps including AcrAB and EmrAB that promote bile tolerance and increase antibiotic efflux [35, 36]. In S. typhimurium, an AcrB-like protein that encodes for an efflux pump contributes to resistance to both bile salts and detergents [37, 38]. Bile exposure in Enterococcus faecalis induces genes encoding for EmrB/QacA family drug resistance transporters and increases expression of phospholipid synthetase which is linked to daptomycin resistance [39]. Thus, increased exposure to bile may be contributing to rising antimicrobial resistance in pathogenic bacteria. However, how these responses impact overall survival is poorly understood.

There are limited studies investigating the responses of Pa, a non-enteric pathogen, to bile. Pa replicates robustly in bile, and bile exposure has been shown to stimulate the production of Pa virulence factors including genes important in biofilm formation, cell envelope biogenesis, quorum sensing, Type VI secretion, and antimicrobial tolerance [19, 34, 40-42]. In the lungs of patients with cystic fibrosis and structural lung disease, bile aspiration is associated with the early acquisition of Pa [43, 44]. Once established in the lungs of such patients, Pa is exceedingly difficult to eradicate as ongoing bile exposure secondary to gastroesophageal reflux potentiates adaptations that allow for persistent colonization [41, 45]. Given that Pa replicates in bile, traffics to the gallbladder following BSI, and is commonly cultured from patients with gallbladder infections, we questioned if the presence of a gallbladder played a role in PABSI outcome. We hypothesized that the gallbladder might facilitate greater Pa exposure to bile and promote the development of antimicrobial resistance. Additionally, we hypothesized that prior cholecystectomy (gallbladder removal) through elimination of an in vivo replication niche, may improve outcomes following PABSI. The purpose of this retrospective analysis was to evaluate the impact of cholecystectomy on AMR development and infection outcomes in patients with PABSI.

MATERIALS AND METHODS

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

Study setting, design, and protocol

In this retrospective cohort study, we examined patients with Pa bloodstream infections hospitalized at Northwestern Memorial Hospital (NMH) and Prentice Women's Hospital from July 1, 2014 to July 1, 2019. NMH is an 894-bed academic medical center with a full range of clinical services including a robust immunocompromised patient population. As Pa is rarely a contaminant in the bloodstream, patients were considered to have PABSI if ≥ 1 blood culture was positive for Pa. The first positive isolate per patient was included in this analysis. Exclusion criteria included: patients aged less than 18 years, those who had undergone a

cholecystectomy within the last 1 year, patients with HIV/AIDS and pregnant women. Patients with polymicrobial bacteremia were included in the study. This project was reviewed and approved by the Northwestern University Institutional Review Board (project no. STU00210641). Inpatient electronic medical records (NMH Enterprise Data Warehouse), pharmacy and microbiology databases were reviewed. Patient demographics included gender, age, and number of days from admission to the first positive blood culture. The presence of the following comorbid conditions was documented: neutropenia, localized solid tumor, metastatic solid tumor, leukemia/lymphoma, myocardial infarction, congestive heart failure, peripheral vascular disease, COPD, chronic kidney disease, diabetes mellitus, CVA/TIA, dementia, hemiplegia, peptic ulcer disease, liver disease, and connective tissue disease. Charlson comorbidity index (CCI) was calculated at the time of bacteremia to estimate illness severity [46]. Charts were reviewed for evidence of cholecystectomy (gallbladder removal) through identification via ICD-9 or ICD-10 code or through absence of a gallbladder on abdominal computed tomography (CT) scan. For patients with a history of cholecystectomy, the approximate procedure date and reason were recorded, if available. Recorded characteristics of BSIs included the suspected source of infection, whether the infection was polymicrobial, and whether the infection was hospital-acquired (nosocomial, onset ≥ 72 hours after admission). The following aspects of antimicrobial therapy were recorded: time to active therapy, length of blood culture positivity, and culture susceptibility to antibiotics spanning seven classes as detailed below. Length of culture positivity was determined by manual chart review. Outcomes included length of blood culture positivity, 90-day and in-hospital mortality if < 90 days.

Microbiology

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

Blood cultures from hospitalized patients were processed by the NMH Microbiology Laboratory using the BacT/ALERT® blood culture system (bioMérieux, Marcy l'Etoile, France), with each set consisting of aerobic and anaerobic cultures. Genus and species identification of bacteria

was performed via mass spectrometry identification using MALDI-TOF (bioMérieux) or manual biochemical assays when necessary. Susceptibility testing was performed by either the Vitek II system to determine minimal inhibitory concentration (MIC) or Kirby Bauer disk diffusion on Mueller-Hinton agar plates. Antimicrobial agents tested included ciprofloxacin, cefepime, ceftazidime, piperacillin/tazobactam, ceftazidime/avibactam, ceftolozane/tazobactam, meropenem, imipenem, aztreonam, amikacin, gentamicin, tobramycin, colistin, polymyxin B, and tigecycline. MICs and zones of inhibition were categorically interpreted according to Clinical and Laboratory Standards Institute (CLSI, 30th edition) guidelines [47].

Definitions

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

Neutropenia was defined as an absolute neutrophil count < 500/mm³ [48]. Nosocomial bacteremia was defined as bacteremia acquired ≥ 72 hours after hospitalization. Polymicrobial bloodstream infection was defined as concurrent isolation of Pa plus any additional bacterium from the bloodstream at time of the diagnostic blood culture. Active antimicrobial therapy was defined as therapy with at least one agent to which the causative Pa strain was susceptible. Specific doses were not reviewed, but all antibiotics were dosed prospectively by clinical pharmacists to optimize efficacy while minimizing safety concerns. Recurrent PABSI was defined as re-isolation of Pa from a patient's bloodstream ≥ 2 weeks from the incident episode provided interval clearance (documented negative blood culture) of the bloodstream between Infections were categorized as multidrug resistant (MDR) if they were nonepisodes. susceptible (either intermediate or resistant) to \geq 1 agent from \geq 3 classes of antibiotics. extensively drug-resistant (XDR) if they were susceptible to ≤ 2 classes of antibiotics, and pandrug resistant (PDR) if non-susceptible to all antibiotics tested following standardized criteria [49]. Culture positivity was analyzed in two ways. First, we recorded the total number of daily positive blood cultures documented regardless of follow up clearance (n=336, all patients). For patients with no blood culture follow-up within 48 hours of index culture, the length of culture

positivity was recorded as 1 day. Second, we analyzed only those patients for whom there was documented follow-up of blood cultures within 48 hours of the index positive culture (n = 220). For patients with recurrent PABSI episodes, the longest consecutive duration of documented positive cultures was included.

Statistical analysis

Statistical analyses were performed using Stata v.17.0 (Statacorp, College Station, Texas). Tables were created with program table1_mc. Results were expressed as mean \pm standard deviation (SD). Pearson's chi-squared test was employed for categorical variables and ANOVA for continuous variables (with appropriate degrees of freedom between groups) to calculate p-values. Tests were two-tailed, and a p-value of \leq 0.05 was used for statistical significance. Length of culture positivity data lacked a parametric distribution, and thus p-values were calculated using the two-sample Wilcon rank-sum (Mann-Whitney) test. Time to event analyses were completed with log rank tests for assessments of equality. Kaplan-Meier curves were generated using GraphPad Prism v9.0.0 (GraphPad Software, San Diego, California, USA).

RESULTS

Patient characteristics

During the study period, 352 episodes of *Pa* bloodstream infection were recorded in 336 unique patients (Table 1) of which twelve patients (3.6%) had recurrent PABSI. The mean age of patients in the study was 66.9 years and 64.3% were male. Nosocomial infections represented 20.8% of all infections and 17.3% of the bacteremia episodes were polymicrobial. Of the individual patients evaluated, 262 (78.0%) had a gallbladder at the time of infection (no cholecystectomy) and 74 (22.0%) had had prior gallbladder removal (cholecystectomy), yielding a ratio of approximately 3:1 of patients with and without a gallbladder at the time of their PABSI. Unsurprisingly given the predilection of females for gallbladder disease, fewer male patients had

prior cholecystectomy (43.2% vs. 70.2%, respectively; P < 0.001). The majority of patients (64.6%) had a Charlson comorbidity Index (CCI) ≥ 5 at the time of their PABSI diagnosis, and the average CCI was 6.4 in patients without a gallbladder and 5.6 in the cohort with a gallbladder (P = 0.026). Generally, the presence of most medical comorbidities was not statistically different between cohorts. However, among patients without a gallbladder, a larger percentage had peripheral vascular disease (20.3% vs. 9.2%, respectively; P = 0.008) and liver disease (16.2% vs. 5.0%, respectively; P = 0.001). A smaller percentage of patients without a gallbladder were neutropenic (8.1% vs. 22.1%, respectively; P = 0.007) or had leukemia or lymphoma (13.5% vs. 25.6%, respectively; P = 0.029). The mean time to active therapy was statistically different between the two groups (1.4 days for patients without a gallbladder vs. 0.6 days for patients with a gallbladder; P = 0.003).

Antimicrobial resistance profiles of PABSI isolates

To discern if prior cholecystectomy was associated with the AMR patterns of our PABSI isolates, we examined the resistance profiles of each isolate. Of the 336 unique episodes of PABSI, we had antimicrobial resistance data for all but 13 (3.9%) which were excluded from this analysis (Table 2). As mentioned, 12 patients (3.6%) had recurrent PABSI during this study period. For patients with recurrence, antibiotic susceptibility data was assessed for each patient's first positive blood culture yielding a total of 323 unique isolates. Overall, for those antibiotics for which we had complete data (ciprofloxacin, cefepime, ceftazidime, piperacillintazobactam, gentamicin and tobramycin), we saw the highest rates of non-susceptibility to ciprofloxacin (48/323, 14.9%) followed closely by piperacillin-tazobactam (39/323, 12.1%). The percentage of non-susceptible isolates for each of the above antibiotics was generally similar among patients with and without a gallbladder. A greater proportion of isolates in patients without a gallbladder were non-susceptible to piperacillin/tazobactam (17.1% vs 10.7%, P = 0.14), gentamicin (12.9% vs. 7.9%, P = 0.20), and colistin (41.7% vs. 30.6%, P = 0.48), though

none of these results achieved statistical significance. Of the 323 isolates, we had meropenem susceptibility data for 282, of which 8.2% were non-susceptible. Very few isolates underwent testing for ceftazidime/avibactam or ceftolozane/tazobactam as the study period was prior to extensive clinical use of these antimicrobial agents. A relatively large percentage of PABSI episodes were characterized as MDR (12.1%) or XDR (4.3%), but there was no statistical difference in MDR or XDR phenotype observed between patients without or with a gallbladder (MDR 12.9% vs. 11.9%, P = 0.82; XDR 2.9% vs. 4.8%, P = 0.49, respectively). No isolates were pan-drug resistant. Overall, across all seven classes of antibiotics, we did not observe statistically significant differences in AMR patterns that were correlated with the presence of a gallbladder at the time of PABSI diagnosis.

The impact of prior cholecystectomy on outcome of PABSI

We examined several outcomes measures in our patient population. There was a statistically significant difference in the time to active therapy in the two study populations (1.4 days for the cohort without a gallbladder vs. 0.6 for the cohort with a gallbladder, P = 0.003) (Table 1). No significant difference in duration of bacteremia was observed between the two populations when analyzing all included patients (n = 336). Average length of culture positivity for the entire cohort was 1.2 days, with averages of 1.5 days for the group lacking a gallbladder and 1.2 days for the group who retained a gallbladder (P = 0.19) (Table 3). We also analyzed a subset of patients for whom we had documented follow up blood cultures within 48 hours of their index positive culture (n = 220). This subset excluded patients who died prior to repeat blood cultures being drawn. Notably, the majority of patients in both populations (cholecystectomy n = 50, no cholecystectomy n = 170) cleared their cultures within 48 hours. Again, no significant difference in culture positivity was observed between cohorts (1.38 \pm 1.2 days vs 1.17 \pm 0.6 days, respectively; P = 0.44). Ninety-day mortality among both patient cohorts was similar (32.4% and 29.4%; P = 0.61), with a considerable number of those patients expiring in the hospital in

both cohorts (23% vs. 20.2%; P = 0.61) (Table 3). Overall, no statistically significant difference was seen between cohorts for 90-day mortality or in-hospital mortality as seen in Kaplan-Maier curves displaying mortality data (P > 0.5) (Fig. 1).

DISCUSSION

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

In this single-institution retrospective cohort study, we assessed the impact of prior gallbladder removal on clinical outcomes and Pa antimicrobial resistance profile following PABSI. No previous studies have investigated the relationship between remote cholecystectomy, development of AMR and PABSI outcomes. Several studies, however, have investigated the impact of cholecystectomy on C. difficile incident infection (CDI), recurrence and mortality [50, 51]. Given that cholecystectomy is associated with increased levels of fecal secondary bile acids which confer resistance to C. difficile infection in animal models, the authors proposed that cholecystectomy might protect against CDI. Patients without a gallbladder did not experience higher rates of incident CDI or recurrence. However, there was a significant increase in mortality in patients following cholecystectomy [51]. The reason for the increase in mortality is poorly understood. Conversely, in our study investigating PABSI, having a prior remote cholecystectomy did not impact clinical outcome as patients with and without a gallbladder had similar durations of bacteremia, in-hospital and 90-day mortality rates. There were baseline differences in the two study populations that may have masked outcome differences. Neutropenia, a known risk factor for poor outcomes in PABSI, and leukemia/lymphoma were more common in patients with a gallbladder, whereas peripheral vascular disease and liver disease (other characteristics associated with poor PABSI outcomes) were more common in patients without one. Furthermore, patients without a gallbladder experienced a longer delay in the onset of active antimicrobial therapy and averaged higher CCI scores at time of PABSI diagnosis. These differences may have offset and contributed to similar outcomes seen in both patient populations. Overall, given these confounders, it is difficult to determine the impact of baseline population differences on outcomes in our study.

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

Additionally, we found no association between prior cholecystectomy and increased antibiotic resistance among PABSI isolates as there were no statistically significant differences in AMR patterns dependent on the presence or absence of a gallbladder at the time of diagnosis. We had theorized that in patients with an intact gallbladder during PABSI, the Pa isolate may have increased bile exposure, a risk factor for the development of AMR [41]. Other pathogens such as E. coli, Klebsiella pneumoniae, and enterococci have displayed unexpected resistance traits when cultured from the gallbladder, and bile exposure has been shown to increase expression of efflux pumps critical for the development of antibacterial resistance [20, 34, 52, 53]. Thus, the lack of increased AMR in patients with a retained gallbladder was surprising. However, several factors may explain this observation. First, the quantity of bile exposure in patients following cholecystectomy is difficult to ascertain. Even in the absence of a gallbladder the liver produces bile which is subsequently excreted into the small intestine. Furthermore, patients who have undergone prior cholecystectomy have had at least one contact with the healthcare system, thereby increasing their exposure to healthcare-associated pathogens which routinely display higher patterns of antimicrobial resistance [54-57]. Finally, it is likely that in a percentage of our cohort, PABSI arose from sites other than the GI tract (e.g. from the lungs or exogenous via indwelling catheters). In these cases, it is unlikely that Pa would have been exposed to bile in either the gallbladder or GI tract prior to infection. These factors may have obscured any differences in AMR related to the presence or absence of a gallbladder.

This study was able to place PABSIs at our institution in historical context as a similar study, completed more than a decade earlier, assessed morbidity associated with PABSI. In that study, the average patient was 57 years old, the in-hospital mortality rate was 37% [9] and one-third of all infections were polymicrobial. By comparison, our cohort was older (average

age 66.9 years), the in-hospital mortality was lower (20.8%), and only 17.3% of all bloodstream infections were polymicrobial. We are encouraged by the 16% decline in the in-hospital mortality rate of PABSI over the last 15 years and believe that there are several factors that have contributed to this decline. First, we believe that recognition of rising rates of AMR, particularly in *Pa* infections, has led to more rapid and aggressive initiation of anti-pseudomonal antibiotics early in the hospital stay in those patients with risk factors for *Pa* infections. Additionally, during the study period, newer combination antimicrobials for *Pa* infections including ceftazidime-avibactam and ceftolozane-tazobactam were introduced (2014 and 2015, respectively). Both have expanded the antibiotic toolkit available to treat MDR and XDR *Pa* infections. Lastly, there are differences in study populations between the two studies. Though our cohort was considerably older than the original study, there was a dramatic reduction in the rate of polymicrobial bloodstream infections. These factors may offset one another; however, our study is not powered to fully assess the impact of these differences on outcomes. Despite the 15-year interval between the two studies, it is important to acknowledge that the overall mortality rate of PABSI remains high.

General estimates suggest that the lifetime prevalence of cholecystectomy is approximately 4.0% overall, 5.3% among women and 2.4% among men [58]. In our cohort, 22.0% of our patients with PABSI had prior cholecystectomy. Contrary to our hypothesis that cholecystectomy may confer protection against PABSI, the disproportionate number of patients without a gallbladder suggests that this population may, in fact, be vulnerable to PABSI or have significant risk factors that predispose them to PABSI.

This study has several important limitations. First, the population size was relatively small and included patients at a single center, and generalizability to larger populations and different clinical settings may be limited. Additionally, the data collected reflected a disproportionate ratio (three to one) of patients with and without a gallbladder with overall rates of cholecystectomy that were five times higher than expected based on general estimates. A

more balanced population and a matched cohort approach may serve to better highlight subtle differences. Secondly, this analysis was limited to the first episode of PABSI observed in each patient. As prior infection predisposes patients to Pa colonization and increases the risk of invasive infection, there may have been colonized individuals in the cohort who were more predisposed to invasive infection [15, 59]. This study did not assess whether cholecystectomy impacts Pa carriage in the gastrointestinal tract, an important risk factor for invasive disease. Bachta, et al. demonstrated that the gallbladder is crucial for fecal excretion of Pa in mice [19]; However, its role in amplification of fecal shedding in humans is unknown. Additionally, most patients received prompt active antimicrobial therapy within one day of their first positive blood culture (mean days to active therapy 0.73 ± 2.1 days), limiting our ability to assess associations between onset of appropriate antimicrobial therapy, underlying resistance patterns and outcomes.

While we did not observe an improvement in PABSI outcomes in patients lacking a gallbladder, we were able to observe improved overall survival rates following PABSIs compared to a prior study at our institution. This suggests that recognition and treatment of PABSI may be improving, but there is still much to learn about carriage, colonization and excretion of *Pa*. Given the observation that the gallbladder promoted increased gastrointestinal excretion of *Pa* in mice, it would be interesting to investigate this question in human patients. A future prospective study comparing fecal carriage of *Pa* in patients with and without a gallbladder following PABSI would help elucidate whether the gallbladder is important for amplification of *Pa* in patients. If the presence of a gallbladder provided an important *in vivo* replication niche and increased excretion of *Pa* this may change the way clinicians approach patients with disseminated *Pa* infections. Such patients might benefit from increased infection control measures that limit environmental contamination of their rooms. Additionally, prophylactic elective cholecystectomy in patients with recurrent BSI or a lower threshold for emergent cholecystectomy in critically ill patients could be entertained. Ultimately, it is critical

that we continue to explore the interplay between the gallbladder, bile exposure and antimicrobial resistance in the context of PABSI to better understand the pathophysiology of BSIs and to enhance our ability to develop new therapeutics in light of rising rates of antimicrobial resistance.

TABLES Table 1: Demographic and clinical characteristics of the study population.

400

Baseline characteristics	All n = 336	Cholecystectomy n = 74	No cholecystectomy n = 262	P-value
	n (%)	n (%)	n (%)	•
Male	216 (64.3)	32 (43.2)	184 (70.2)	<0.001
Age, y, mean (SD)	66.9 (16.3)	68.3 (18.2)	66.5 (15.7)	0.39
Nosocomial infection ^a	70 (20.8)	18 (24.3)	52 (19.8)	0.40
Polymicrobial infection	58 (17.3)	17 (23.0)	41 (15.6)	0.14
Charlson comorbidity index ^b , mean				
(SD)	5.7 (2.8)	6.4 (3.0)	5.6 (2.7)	0.026
1-2 points	32 (9.5)	5 (6.8)	27 (10.3)	
3-4 points	79 (23.5)	12 (16.2)	67 (25.6)	
≥5 points	217 (64.6)	54 (73.0)	163 (62.2)	
Days to active therapy, mean (SD)	0.73 (2.1)	1.40 (3.5)	0.55 (1.4)	0.003
Medical comorbidity				
Neutropenic (ANC <500/mm ³)	64 (19.0)	6 (8.1)	58 (22.1)	0.007
Localized solid tumor	50 (14.9)	10 (13.5)	40 (15.3)	0.71
Metastatic solid tumor	48 (14.3)	13 (17.6)	35 (13.4)	0.36
Leukemia/lymphoma	77 (22.9)	10 (13.5)	67 (25.6)	0.029
Myocardial infarction	58 (17.3)	13 (17.6)	45 (17.2)	0.94
Congestive heart failure	87 (25.9)	23 (31.1)	64 (24.4)	0.25
Peripheral vascular disease	39 (11.6)	15 (20.3)	24 (9.2)	0.008
COPD	47 (14.0)	14 (18.9)	33 (12.6)	0.17
Chronic kidney disease	44 (13.1)	7 (9.5)	37 (14.1)	0.29
Diabetes mellitus	94 (28.0)	24 (32.4)	70 (26.7)	0.33
CVA/TIA	52 (15.5)	13 (17.6)	39 (14.9)	0.57
Dementia	19 (5.7)	5 (6.8)	14 (5.3)	0.64
Hemiplegia	13 (3.9)	2 (2.7)	11 (4.2)	0.56
Peptic ulcer disease	10 (3.0)	1 (1.4)	9 (3.4)	0.35
Liver disease	25 (7.4)	12 (16.2)	13 (5.0)	0.001
Connective tissue disease	16 (4.8)	4 (5.4)	12 (4.6)	0.77

^aNosocomial infection was defined as culture positivity after ≥72 hours of hospital stay.

^bThe Charlson comorbidity index (CCI) was computed on the day of the first positive blood culture.

Table 2: Antibiotic susceptibility patterns in patients with and without prior cholecystectomy

403

	Non-susceptible ^a isolates, n/N (%)			
Antibiotic	AII n = 323 ^b	Cholecystectomy n = 70 ^b	No cholecystectomy n = 253 ^b	P-value
Fluoroquinolones	-			•
Ciprofloxacin	48/323 (14.9)	10/70 (14.3)	38/253 (15.0)	0.88
Cephalosporins				
Cefepime	34/323 (10.5)	8/70 (11.4)	26/253 (10.3)	0.78
Ceftazidime	27/323 (8.4)	6/70 (8.6)	21/253 (8.3)	0.94
B-lactam/B-lactamase inhibitor				
Piperacillin/Tazobactam	39/323 (12.1)	12/70 (17.1)	27/253 (10.7)	0.14
Ceftazidime/Avibactam	0/2 (0.0)	0/0 (n/a)	0/2 (0.0)	n/a
Ceftolozane/Tazobactam	0/2 (0.0)	0/0 (n/a)	0/2 (0.0)	n/a
Carbapenems				
Meropenem	23/282 (8.2)	4/60 (6.7)	19/222 (8.6)	0.63
Imipenem	7/40 (17.5)	1/9 (11.1)	6/31 (19.4)	0.57
Monobactam				
Aztreonam	90/322 (28.0)	19/70 (27.1)	71/252 (28.2)	0.86
Aminoglycosides				
Amikacin	5/206 (2.4)	0/43 (0.0)	5/163 (3.1)	0.24
Gentamicin	29/323 (9.0)	9/70 (12.9)	20/253 (7.9)	0.20
Tobramycin	16/323 (5.0)	4/70 (5.7)	12/253 (4.7)	0.74
Polymyxins				
Colistin	16/48 (33.3)	5/12 (41.7)	11/36 (30.6)	0.48
Polymyxin B	2/7 (28.6)	0/0 (n/a)	2/7 (28.6)	n/a
Tigecycline	46/47 (97.9)	16/17 (94.1)	30/30 (100)	0.18
MDR^c	39/323 (12.1)	9/70 (12.9)	30/252 (11.9)	0.82
XDR ^c	14/323 (4.3)	2/70 (2.9)	12/252 (4.8)	0.49

^aStrains were designated as susceptible, intermediate, or resistant following the CLSI guidelines (M100 Performance Standards for Antimicrobial Susceptibility Testing, 30th Edition). All intermediate or resistant strains were categorized as non-susceptible and are included in this table.

^bThere were 336 unique patients, some with multiple positive cultures. For those patients (n = 12), only the resistance profile of the first episode was included. Thirteen episodes were missing ABX resistance data and were excluded from this table. This included 4 episodes from patients who had undergone a cholecystectomy and 9 who had not.

^cMultidrug-resistance (MDR) was defined as isolates non-susceptible to ≥1 agent from ≥3 classes of antibiotics and extensively drug-resistance (XDR) was defined as isolates susceptible to ≤2 classes of antibiotics tested

Table 3: Outcomes in patients with and without prior cholecystectomy

405

Patient outcomes	AII n = 336	Cholecystectomy n = 74	No cholecystectomy n = 262	P-value
	n (%)	n (%)	n (%)	=
Length of culture				
positivity, mean (SD) ^a	1.24 (0.8)	1.46 (1.3)	1.18 (0.6)	0.19
90-day mortality	101 (30.1)	24 (32.4)	77 (29.4)	0.61
In-hospital mortality	70 (20.8)	17 (23.0)	53 (20.2)	0.61

^aFor patients with recurrent episodes, the longest duration of positive cultures was recorded.

FIGURES




Fig. 1 Mortality in Patients with *Pa* **Bacteremia.** Patients are stratified by history of gallbladder removal (cholecystectomy, gray) or retained gallbladder (black). Results are displayed as a function of 90-day mortality (**A**) and in-hospital mortality (**B**). P-value are >0.5 for both graphs. Day 0 is the day of first positive blood culture

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

STATEMENTS AND DECLARATIONS Ethics approval and consent to participate This research study (STU00210641) was reviewed by the Northwestern University Institutional Review Board and was deemed an observational study where no ethical approval was required. **Competing interests** H.K.B., L.R.H., M.P.A., A.R.H., M.S., and K.E.R.B declare that they have no relevant competing interests. **Funding** This work was supported by grants from an American Cancer Society (ACS) Clinician Scientist Development Grant (#134251-CSDG-20-053-01-MPC, awarded to K.E.R.B.), and a Pilot Award from the Northwestern Enterprise Data Warehouse (awarded to L.R.H.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. **Authors' contributions** The authors confirm contribution to the paper as follows: study conception and design: L.R.H., M.P.A., A.R.H., and K.E.R.B; data collection: H.K.B., L.R.H., and K.E.R.B.; analysis and interpretation of results: H.K.B., M.S., L.R.H., and K.E.R.B; draft manuscript preparation: H.K.B., M.S., and K.E.R.B. All authors reviewed the results and approved the final version of the manuscript.

REFERENCES

- 440 1. Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial
- bloodstream infection in North America and Europe. Clin Microbiol Infect. 2013 Jun;19(6):501-9.
- 442 PubMed PMID: 23473333. Epub 20130308.
- 2. Riu M, Chiarello P, Terradas R, Sala M, Garcia-Alzorriz E, Castells X, et al. Cost
- 444 Attributable to Nosocomial Bacteremia. Analysis According to Microorganism and Antimicrobial
- Sensitivity in a University Hospital in Barcelona. PLoS One. 2016;11(4):e0153076. PubMed
- 446 PMID: 27055117. Pubmed Central PMCID: PMC4824502. Epub 20160407.
- 447 3. Torio CM, Moore BJ. National Inpatient Hospital Costs: The Most Expensive Conditions
- by Payer, 2013. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD)2006.
- 450 4. Hall MJ, Williams SN, DeFrances CJ, Golosinskiy A. Inpatient care for septicemia or
- sepsis: a challenge for patients and hospitals. NCHS Data Brief. 2011 Jun(62):1-8. PubMed
- 452 PMID: 22142805.
- 5. Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, et al. The
- 454 Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial
- Surveillance Program. Antimicrob Agents Chemother. 2019 Jul;63(7). PubMed PMID:
- 456 31010862. Pubmed Central PMCID: PMC6591610. Epub 20190624.
- 457 6. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial
- 458 bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide
- surveillance study. Clin Infect Dis. 2004 Aug 1;39(3):309-17. PubMed PMID: 15306996. Epub 20040715.
- 461 7. Thaden JT, Park LP, Maskarinec SA, Ruffin F, Fowler VG, Jr., van Duin D. Results from
- 462 a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream
- Infections Caused by *Pseudomonas aeruginosa* Compared to Other Bacteria. Antimicrob
- Agents Chemother. 2017 Jun;61(6). PubMed PMID: 28373189. Pubmed Central PMCID:
- 465 PMC5444115. Epub 20170524.
- 466 8. Ani C, Farshidpanah S, Bellinghausen Stewart A, Nguyen HB. Variations in organism-
- specific severe sepsis mortality in the United States: 1999-2008. Crit Care Med. 2015
- 468 Jan;43(1):65-77. PubMed PMID: 25230374.
- 469 9. Scheetz MH, Hoffman M, Bolon MK, Schulert G, Estrellado W, Baraboutis IG, et al.
- 470 Morbidity associated with *Pseudomonas aeruginosa* bloodstream infections. Diagn Microbiol
- 471 Infect Dis. 2009 Jul;64(3):311-9. PubMed PMID: 19345039. Pubmed Central PMCID:
- 472 PMC2693471. Epub 20090402.
- 473 10. Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE. Treatment and outcome of
- 474 Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob
- 475 Chemother. 2003 Oct;52(4):668-74. PubMed PMID: 12951354. Epub 20030901.
- 476 11. Kuikka A, Valtonen VV. Factors associated with improved outcome of *Pseudomonas*
- 477 aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis. 1998
- 478 Oct;17(10):701-8. PubMed PMID: 9865983.
- 479 12. Holmes CL, Anderson MT, Mobley HLT, Bachman MA. Pathogenesis of Gram-Negative
- Bacteremia. Clin Microbiol Rev. 2021 Jun 16;34(2). PubMed PMID: 33692149. Pubmed Central
- 481 PMCID: PMC8549824. Epub 20210310.
- 482 13. Girmenia C, Bertaina A, Piciocchi A, Perruccio K, Algarotti A, Busca A, et al. Incidence,
- 483 Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and
- 484 Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey.
- 485 Clin Infect Dis. 2017 Nov 13;65(11):1884-96. PubMed PMID: 29020286.
- 486 14. Gomez-Zorrilla S, Camoez M, Tubau F, Canizares R, Periche E, Dominguez MA, et al.
- 487 Prospective observational study of prior rectal colonization status as a predictor for subsequent
- development of *Pseudomonas aeruginosa* clinical infections. Antimicrob Agents Chemother.

- 489 2015 Sep;59(9):5213-9. PubMed PMID: 26077248. Pubmed Central PMCID: PMC4538513.
- 490 Epub 20150615.
- 491 15. Hoang S, Georget A, Asselineau J, Venier AG, Leroyer C, Rogues AM, et al. Risk
- 492 factors for colonization and infection by *Pseudomonas aeruginosa* in patients hospitalized in
- 493 intensive care units in France. PLoS One. 2018;13(3):e0193300. PubMed PMID: 29522559.
- 494 Pubmed Central PMCID: PMC5844558. Epub 20180309.
- 495 16. Bang JH, Jung Y, Cheon S, Kim CJ, Song KH, Choe PG, et al. *Pseudomonas*
- 496 aeruginosa bacteremia in patients with liver cirrhosis: a comparison with bacteremia caused by
- 497 Enterobacteriaceae. BMC Infect Dis. 2013 Jul 19;13:332. PubMed PMID: 23870005. Pubmed
- 498 Central PMCID: PMC3720192. Epub 20130719.
- 499 17. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, et al. *Pseudomonas aeruginosa*
- bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial
- therapy on clinical outcome. Clin Infect Dis. 2003 Sep 15;37(6):745-51. PubMed PMID:
- 502 12955633. Epub 20030823.
- 503 18. Sung YK, Lee JK, Lee KH, Lee KT, Kang CI. The clinical epidemiology and outcomes of
- 504 bacteremic biliary tract infections caused by antimicrobial-resistant pathogens. Am J
- 505 Gastroenterol. 2012 Mar;107(3):473-83. PubMed PMID: 22334249. Epub 20120214.
- 506 19. Bachta KER, Allen JP, Cheung BH, Chiu CH, Hauser AR. Systemic infection facilitates
- transmission of *Pseudomonas aeruginosa* in mice. Nat Commun. 2020 Jan 28;11(1):543.
- 508 PubMed PMID: 31992714. Pubmed Central PMCID: PMC6987207. Epub 20200128.
- 509 20. Maseda E, Maggi G, Gomez-Gil R, Ruiz G, Madero R, Garcia-Perea A, et al. Prevalence
- of and risk factors for biliary carriage of bacteria showing worrisome and unexpected resistance
- traits. J Clin Microbiol. 2013 Feb;51(2):518-21. PubMed PMID: 23196362. Pubmed Central
- 512 PMCID: PMC3553897. Epub 20121128.
- 513 21. Malorni W, Paradisi S, Dupuis ML, Fiorentini C, Ramoni C. Enhancement of cell-
- 514 mediated cytotoxicity by Clostridium difficile toxin A: an in vitro study. Toxicon. 1991;29(4-
- 515 5):417-28. PubMed PMID: 1907410.
- 516 22. Voigtlander T, Leuchs E, Vonberg RP, Solbach P, Manns MP, Suerbaum S, et al.
- 517 Microbiological analysis of bile and its impact in critically ill patients with secondary sclerosing
- 518 cholangitis. J Infect. 2015 May;70(5):483-90. PubMed PMID: 25659761. Epub 20150207.
- 519 23. Reshetnyak VI. Physiological and molecular biochemical mechanisms of bile formation.
- 520 World J Gastroenterol. 2013 Nov 14;19(42):7341-60. PubMed PMID: 24259965. Pubmed
- 521 Central PMCID: PMC3831216.
- 522 24. Sistrunk JR, Nickerson KP, Chanin RB, Rasko DA, Faherty CS. Survival of the Fittest:
- How Bacterial Pathogens Utilize Bile To Enhance Infection. Clin Microbiol Rev. 2016
- 524 Oct;29(4):819-36. PubMed PMID: 27464994. Pubmed Central PMCID: PMC5010752.
- 525 25. Gonzalez-Escobedo G, Marshall JM, Gunn JS. Chronic and acute infection of the gall
- 526 bladder by Salmonella Typhi: understanding the carrier state. Nat Rev Microbiol. 2011
- Jan;9(1):9-14. PubMed PMID: 21113180. Pubmed Central PMCID: PMC3255095. Epub
- 528 20101129.
- 529 26. Zhang T, Abel S, Abel Zur Wiesch P, Sasabe J, Davis BM, Higgins DE, et al.
- 530 Deciphering the landscape of host barriers to *Listeria monocytogenes* infection. Proc Natl Acad
- Sci U S A. 2017 Jun 13;114(24):6334-9. PubMed PMID: 28559314. Pubmed Central PMCID:
- 532 PMC5474794. Epub 20170530.
- 533 27. Gahan CG, Hill C. Listeria monocytogenes: survival and adaptation in the
- 534 gastrointestinal tract. Front Cell Infect Microbiol. 2014;4:9. PubMed PMID: 24551601. Pubmed
- 535 Central PMCID: PMC3913888. Epub 20140205.
- 536 28. Menendez A, Arena ET, Guttman JA, Thorson L, Vallance BA, Vogl W, et al. Salmonella
- 537 infection of gallbladder epithelial cells drives local inflammation and injury in a model of acute
- typhoid fever. J Infect Dis. 2009 Dec 1;200(11):1703-13. PubMed PMID: 19852670.

- 539 29. Hardy J, Francis KP, DeBoer M, Chu P, Gibbs K, Contag CH. Extracellular replication of
- Listeria monocytogenes in the murine gall bladder. Science. 2004 Feb 6;303(5659):851-3.
- 541 PubMed PMID: 14764883.
- 542 30. Briones V, Blanco MM, Marco A, Prats N, Fernandez-Garayzabal JF, Suarez G, et al.
- 543 Biliary excretion as possible origin of *Listeria monocytogenes* in fecal carriers. Am J Vet Res.
- 544 1992 Feb;53(2):191-3. PubMed PMID: 1575382.
- 545 31. Hardy J, Margolis JJ, Contag CH. Induced biliary excretion of *Listeria monocytogenes*.
- Infect Immun. 2006 Mar;74(3):1819-27. PubMed PMID: 16495556. Pubmed Central PMCID:
- 547 PMC1418634.
- 548 32. Dussurget O, Cabanes D, Dehoux P, Lecuit M, Buchrieser C, Glaser P, et al. Listeria
- 549 monocytogenes bile salt hydrolase is a PrfA-regulated virulence factor involved in the intestinal
- and hepatic phases of listeriosis. Mol Microbiol. 2002 Aug;45(4):1095-106. PubMed PMID:
- 551 12180927.
- 552 33. Gonzalez-Escobedo G, Gunn JS. Gallbladder epithelium as a niche for chronic
- 553 Salmonella carriage. Infect Immun. 2013 Aug;81(8):2920-30. PubMed PMID: 23732169.
- 554 Pubmed Central PMCID: PMC3719562. Epub 20130603.
- 555 34. Gipson KS, Nickerson KP, Drenkard E, Llanos-Chea A, Dogiparthi SK, Lanter BB, et al.
- 556 The Great ESKAPE: Exploring the Crossroads of Bile and Antibiotic Resistance in Bacterial
- Pathogens. Infect Immun. 2020 Sep 18;88(10). PubMed PMID: 32661122. Pubmed Central
- 558 PMCID: PMC7504946. Epub 20200918.
- 559 35. Nikaido H, Zgurskaya HI. AcrAB and related multidrug efflux pumps of Escherichia coli. J
- Mol Microbiol Biotechnol. 2001 Apr;3(2):215-8. PubMed PMID: 11321576.
- 561 36. Piddock LJ. Multidrug-resistance efflux pumps not just for resistance. Nat Rev
- 562 Microbiol. 2006 Aug;4(8):629-36. PubMed PMID: 16845433.
- 563 37. Lacroix FJ, Cloeckaert A, Grepinet O, Pinault C, Popoff MY, Waxin H, et al. Salmonella
- 564 *typhimurium* acrB-like gene: identification and role in resistance to biliary salts and detergents
- and in murine infection. FEMS Microbiol Lett. 1996 Jan 15;135(2-3):161-7. PubMed PMID:
- 566 8595853.
- 567 38. Bhattacharyya R, Das K, Sen S, Roy S, Majumder HK. Development of a genus specific
- primer set for detection of Leishmania parasites by polymerase chain reaction. FEMS Microbiol
- Lett. 1996 Jan 15;135(2-3):195-200. PubMed PMID: 8595858.
- 570 39. Zhang X, Bierschenk D, Top J, Anastasiou I, Bonten MJ, Willems RJ, et al. Functional
- 571 genomic analysis of bile salt resistance in *Enterococcus faecium*. BMC Genomics. 2013 May
- 3;14:299. PubMed PMID: 23641968. Pubmed Central PMCID: PMC3653699. Epub 20130503.
- Reen FJ, Flynn S, Woods DF, Dunphy N, Chroinin MN, Mullane D, et al. Bile signalling
- 574 promotes chronic respiratory infections and antibiotic tolerance. Sci Rep. 2016 Jul 19;6:29768.
- 575 PubMed PMID: 27432520. Pubmed Central PMCID: PMC4949476. Epub 20160719.
- 576 41. Flynn S, Reen FJ, O'Gara F. Exposure to Bile Leads to the Emergence of Adaptive
- 577 Signaling Variants in the Opportunistic Pathogen *Pseudomonas aeruginosa*. Front Microbiol.
- 578 2019;10:2013. PubMed PMID: 31555243. Pubmed Central PMCID: PMC6727882. Epub
- 579 20190829.
- 580 42. Behroozian S, Sampedro I, Dhodary B, Her S, Yu Q, Stanton BA, et al. *Pseudomonas*
- 581 aeruginosa PAO1 Is Attracted to Bovine Bile in a Novel, Cystic Fibrosis-Derived Bronchial
- 582 Epithelial Cell Model. Microorganisms. 2022 Mar 26;10(4). PubMed PMID: 35456767. Pubmed
- 583 Central PMCID: PMC9032244. Epub 20220326.
- 584 43. Vos R, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE, Verleden GM. Transient
- airway colonization is associated with airway inflammation after lung transplantation. Am J
- 586 Transplant. 2007 May:7(5):1278-87. PubMed PMID: 17456203.
- 587 44. Vos R, Blondeau K, Vanaudenaerde BM, Mertens V, Van Raemdonck DE, Sifrim D, et
- al. Airway colonization and gastric aspiration after lung transplantation: do birds of a feather
- flock together? J Heart Lung Transplant. 2008 Aug;27(8):843-9. PubMed PMID: 18656796.

- 590 45. Reen FJ, Woods DF, Mooij MJ, Adams C, O'Gara F. Respiratory pathogens adopt a
- 591 chronic lifestyle in response to bile. PLoS One. 2012;7(9):e45978. PubMed PMID: 23049911.
- 592 Pubmed Central PMCID: PMC3458808. Epub 20120926.
- 593 46. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity
- index. J Clin Epidemiol. 1994 Nov;47(11):1245-51. PubMed PMID: 7722560.
- 595 47. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 31st ed. ed. USA:
- 596 Clinical and Laboratory Standards Institute; 2021.
- 597 48. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002
- 598 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis.
- 599 2002 Mar 15;34(6):730-51. PubMed PMID: 11850858. Epub 20020213.
- 600 49. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al.
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international
- expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect.
- 603 2012 Mar;18(3):268-81. PubMed PMID: 21793988. Epub 20110727.
- 604 50. Wang Y, Li J, Zachariah P, Abrams J, Freedberg DE. Relationship between remote
- cholecystectomy and incident *Clostridioides difficile* infection. Clin Microbiol Infect. 2019
- 606 Aug;25(8):994-9. PubMed PMID: 30583059. Pubmed Central PMCID: PMC6589130. Epub 20181222.
- 51. Franko J, Ferrel B, Pierson P, Raman S, Frankova D, Rearigh LM, et al. Influence of
- prior appendectomy and cholecystectomy on Clostridioides difficile infection recurrence and
- 610 mortality. Am J Surg. 2020 Jul;220(1):203-7. PubMed PMID: 31668774. Epub 20191023.
- 611 52. Kwon W, Jang JY, Kim EC, Park JW, Han IW, Kang MJ, et al. Changing trend in bile
- 612 microbiology and antibiotic susceptibilities: over 12 years of experience. Infection. 2013
- 613 Feb;41(1):93-102. PubMed PMID: 23180506. Epub 20121121.
- 614 53. Wulkersdorfer B, Jaros D, Eberl S, Poschner S, Jager W, Cosentini E, et al. Human Bile
- 615 Reduces Antimicrobial Activity of Selected Antibiotics against Enterococcus faecalis and
- 616 Escherichia coli In Vitro. Antimicrob Agents Chemother. 2017 Aug;61(8). PubMed PMID:
- 617 28559254. Pubmed Central PMCID: PMC5527593. Epub 20170725.
- 54. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-
- associated bacterial pneumonia. Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S81-7. PubMed PMID:
- 620 20597676.

- 621 55. Mehrad B, Clark NM, Zhanel GG, Lynch JP, 3rd. Antimicrobial resistance in hospital-
- acquired gram-negative bacterial infections. Chest. 2015 May;147(5):1413-21. PubMed PMID:
- 623 25940252. Pubmed Central PMCID: PMC4420185.
- 56. Sartelli M, Catena F, Coccolini F, Pinna AD. Antimicrobial management of intra-
- abdominal infections: literature's guidelines. World J Gastroenterol. 2012 Mar 7;18(9):865-71.
- PubMed PMID: 22408344. Pubmed Central PMCID: PMC3297044.
- 57. Suna N, Yildiz H, Yuksel M, Parlak E, Disibeyaz S, Odemis B, et al. The change in
- 628 microorganisms reproducing in bile and blood culture and antibiotic susceptibility over the years.
- 629 Turk J Gastroenterol. 2014 Jun;25(3):284-90. PubMed PMID: 25141317.
- 630 58. Alves KR, Goulart AC, Ladeira RM, Oliveira IR, Bensenor IM. Frequency of
- cholecystectomy and associated sociodemographic and clinical risk factors in the ELSA-Brasil
- 632 study. Sao Paulo Med J. 2016 May-Jun;134(3):240-50. PubMed PMID: 27355799. Pubmed
- 633 Central PMCID: PMC10496596. Epub 2016/06/30.
- 634 59. Ohara T, Itoh K. Significance of *Pseudomonas aeruginosa* colonization of the
- 635 gastrointestinal tract. Intern Med. 2003 Nov;42(11):1072-6. PubMed PMID: 14686744.